Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases
暂无分享,去创建一个
Won-Tak Choi | Won-Tak Choi | J. An | Jing An
[1] 村上 努. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection , 1998 .
[2] M. Parmentier,et al. Characterization of the role of the N-loop of MIP-1β in CCR5 binding , 2002 .
[3] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[4] Zi-Xuan Wang,et al. CXCR4 Sequences Involved in Coreceptor Determination of Human Immunodeficiency Virus Type-1 Tropism , 1998, The Journal of Biological Chemistry.
[5] R. Weiss,et al. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion , 1997, Journal of virology.
[6] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[7] N. Aiyar,et al. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.
[8] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[9] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[10] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[11] C. Boshoff,et al. Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.
[12] R. Cooke,et al. The three-dimensional solution structure of RANTES. , 1995, Biochemistry.
[13] W. O'brien,et al. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions , 1996, Journal of virology.
[14] D. Dimitrov,et al. Evidence for Cell-Surface Association Between Fusin and the CD4-gp120 Complex in Human Cell Lines , 1996, Science.
[15] N. Heveker,et al. Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.
[16] E. Fernandez,et al. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 “fusin” coreceptor , 1998 .
[17] T. Schwartz,et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. , 1997, Science.
[18] A. Trautmann,et al. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides , 1998, Current Biology.
[19] R. Doms,et al. A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.
[20] R. Redfield,et al. Clinical use of CCR5 inhibitors in HIV and beyond , 2011, Journal of Translational Medicine.
[21] P. Murphy. The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.
[22] M. Kavanaugh,et al. A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1* , 1999, The Journal of Biological Chemistry.
[23] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[24] Oliver Hartley,et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] B. Sykes,et al. Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.
[26] Zhaowen Luo,et al. Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.
[27] J. Sodroski,et al. Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines* , 2002, The Journal of Biological Chemistry.
[28] E. Berger,et al. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. , 2004, Blood.
[29] Stephen C Peiper,et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. , 2003, Angewandte Chemie.
[30] R. Redfield,et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.
[31] M. Peitsch,et al. Selectivity and antagonism of chemokine receptors , 1996, Journal of leukocyte biology.
[32] B. Dewald,et al. N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities* , 1998, Journal of Biological Chemistry.
[33] D. Richman,et al. SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. , 2006, Chemistry & biology.
[34] M. Matsuoka,et al. Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist , 2006, The Journal of Immunology.
[35] J. Hall,et al. Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide. , 1999, Biochemical and biophysical research communications.
[36] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[37] Marc Parmentier,et al. The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.
[38] Timothy N. C. Wells,et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] R. Doms,et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Lederman,et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. , 2008, The Journal of infectious diseases.
[41] James W. Hall,et al. Molecular modeling and site‐directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction , 2000, European journal of immunology.
[42] John P. Moore,et al. Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[43] H. Dohlman,et al. Identification of Allosteric Peptide Agonists of CXCR4* , 2003, The Journal of Biological Chemistry.
[44] J. Gershoni,et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] A. LiWang,et al. The solution structure of the anti‐HIV chemokine vMIP‐II , 1999, Protein science : a publication of the Protein Society.
[46] R. Weiss,et al. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus , 1991, Virology.
[47] D. S. Garrett,et al. High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.
[48] Won-Tak Choi,et al. Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.
[49] William C. Olson,et al. Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.
[50] M. Kaul,et al. Neuronal Apoptotic Signaling Pathways Probed and Intervened by Synthetically and Modularly Modified (SMM) Chemokines* , 2007, Journal of Biological Chemistry.
[51] Robin A. Weiss,et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.
[52] R. Doms,et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.
[53] Z. Luo,et al. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. , 2000, Biochemistry.
[54] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[55] D. Thompson,et al. Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4. , 2000, Virology.
[56] C. Strader,et al. Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.
[57] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[58] David W. Ritchie,et al. Modeling the Structural Basis of Human CCR5 Chemokine Receptor Function: From Homology Model Building and Molecular Dynamics Validation to Agonist and Antagonist Docking , 2006, J. Chem. Inf. Model..
[59] Elias Lolis,et al. Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.
[60] Ying Li,et al. Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus and d-Amino Acid-Containing Chemokine , 2007, Journal of Virology.
[61] S. Climie,et al. Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. , 1995, Drugs under experimental and clinical research.
[62] Q. Sattentau,et al. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.
[63] T. Schulz,et al. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? , 1991, AIDS research and human retroviruses.
[64] J. Karn,et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[65] C. Boshoff,et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.
[66] G. Lambeau,et al. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. , 2001, Molecular pharmacology.
[67] B. Premack,et al. Chemokine receptors: Gateways to inflammation and infection , 1996, Nature Medicine.
[68] J. Sodroski,et al. A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.
[69] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[70] M. Matsuoka,et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. , 2001, Bioorganic & medicinal chemistry letters.
[71] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[72] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[73] James W. Hall,et al. The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. , 1999, Biochemical and Biophysical Research Communications - BBRC.
[74] J. Goudsmit,et al. ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY , 1989, The Lancet.
[75] J. Demartino,et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[76] Helen M. Blau,et al. Biological Progression from Adult Bone Marrow to Mononucleate Muscle Stem Cell to Multinucleate Muscle Fiber in Response to Injury , 2002, Cell.
[77] B. Cullen,et al. HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.
[78] Thomas P. Sakmar,et al. Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.
[79] Anandan Palani,et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. , 2006, Virology.
[80] C. Broder,et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.
[81] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[82] M. Maccoss,et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. , 2003, Biochemistry.
[83] N. Heveker,et al. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity , 1997, Journal of virology.
[84] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[85] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[86] E. Fernandez,et al. Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation. , 2000, Biochemistry.
[87] Z. Huang,et al. Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. , 2000, Pharmacology & therapeutics.
[88] R. Bronson,et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[89] M. Goldsmith,et al. Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.
[90] Marc Parmentier,et al. Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.
[91] M. Baggiolini,et al. HIV blocked by chemokine antagonist , 1996, Nature.
[92] Menico Rizzi,et al. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES , 2001, Nature Structural Biology.
[93] Stephen C. Peiper,et al. Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions , 1999, Journal of Virology.
[94] M. Parmentier,et al. CC chemokine MIP-1 beta can function as a monomer and depends on Phe13 for receptor binding. , 2000, Biochemistry.
[95] M. Parmentier,et al. Characterization of the role of the N-loop of MIP-1 beta in CCR5 binding. , 2002, Biochemistry.
[96] C. Broder,et al. Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry* , 2000, The Journal of Biological Chemistry.
[97] S. O. Smith,et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[98] Antonio Carrieri,et al. Biological Profiling of Anti‐HIV Agents and Insight into CCR5 Antagonist Binding Using in silico Techniques , 2009, ChemMedChem.
[99] B Dewald,et al. Human chemokines: an update. , 1997, Annual review of immunology.
[100] J. Hoxie,et al. Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. , 1997, Virology.
[101] R. Offord,et al. Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide , 2008, Proceedings of the National Academy of Sciences.
[102] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[103] F. de Wolf,et al. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV‐1 phenotype , 1992, AIDS.
[104] C. Broder,et al. Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates , 1999, Journal of Virology.
[105] S. Mummidi,et al. CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants , 1997, The Journal of Biological Chemistry.
[106] A. Maynard,et al. Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function* , 1999, The Journal of Biological Chemistry.
[107] M. Kaul,et al. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[108] M. Goldsmith,et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[109] B. Kobilka,et al. Adrenergic receptors as models for G protein-coupled receptors. , 1992, Annual review of neuroscience.
[110] Won-Tak Choi,et al. Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.
[111] A. Proudfoot. Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.
[112] Shoshana J. Wodak,et al. The TXP Motif in the Second Transmembrane Helix of CCR5 , 2001, The Journal of Biological Chemistry.
[113] S. Nishikawa,et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.
[114] Marc Parmentier,et al. The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.
[115] J. Hall,et al. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. , 2000, Biochemistry.